HER2+ Breast Cancer | Specialty

Overcoming Resistance in Breast Cancer

June 17th 2015

Improving Endocrine Treatment Decisions in ER+ Breast Cancer

June 17th 2015

Fulvestrant in HR-Positive Breast Cancer

June 17th 2015

Palbociclib in Metastatic Breast Cancer

June 17th 2015

Tumor-Infiltrating Lymphocytes in Breast Cancer

June 17th 2015

Multigene Panel Testing in Breast Cancer

June 17th 2015

Introduction: Biomarkers in Breast Cancer

June 17th 2015

Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study

June 2nd 2015

Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer

May 31st 2015

In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.

Hurvitz Looks Back and Ahead at Advances in Treating HER2-Positive Breast Cancer

May 26th 2015

In a recent interview with AJHO, Sara A. Hurvitz, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer and what the future might hold.

Dr. Pegram on Sequencing Therapies in HER2-Positive Breast Cancer

May 21st 2015

Mark D. Pegram, MD, director, Breast Cancer Oncology Program, Stanford Cancer Institute, discusses contemporary sequencing of therapies for HER2-positive breast cancer.

Krop Takes Stock of Targeted Therapy Advances in HER2-Positive Breast Cancer

May 20th 2015

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.

Study Offers Solution for HER2 Resistance in Breast Cancer

May 19th 2015

By targeting the HER2 protein's ability to transform cells, therapies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) have significantly extended the survival of women with HER2-positive breast cancer. However, major treatment challenges still remain for this breast cancer subtype, according to Ruth Lupu, PhD, professor of Laboratory Medicine and Pathology at Mayo Clinic.

Phase III Trial of Breast Cancer Vaccine Nelipepimut-S Now Fully Enrolled, Mittendorf Discusses Next Steps

April 22nd 2015

OncLive spoke with Elizabeth A. Mittendorf, MD, PhD, to learn more about the PRESENT trial and the potential impact of nelipepimut-S in breast cancer.

Dr. Mittendorf on Nelipepimut-S in Breast Cancer

April 21st 2015

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses nelipepimut-S (NeuVax) and a proposed trial for patients with ductal carcinoma in situ (DCIS).

MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer

April 20th 2015

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

BET Bromodomain Inhibitors May Prevent Treatment Resistance in HER2-Positive Breast Cancer

April 14th 2015

Gary L. Johnson, PhD, discusses how BET bromodomain inhibitors could offer a potential solution to lapatinib resistance in patients with HER2-postive breast cancer.

Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm

April 1st 2015

Patients with advanced cancers of the pancreas or prostate, or where progression to this state occurs later in the course of the illness, should have tumor or germline testing performed looking for the presence of a BRCA mutation.

mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast Cancer

March 27th 2015

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Pegram Discusses Optimal Pertuzumab Use in HER2-Positive Breast Cancer

March 24th 2015

In an interview with OncLive, Mark D. Pegram, MD, discusses what available data suggest is the optimal use of pertuzumab for the management of HER2-positive breast cancer.